IP Library Granted Patent US 10,563,254
Granted Patent B2
US 10,563,254 · App. 12/524,261 · Granted Feb 18, 2020

Nucleic acid amplification and testing

Inventors: Helen Hwai-an Lee (Cambridge, GB); Magda Anastassova Dineva (Cambridge, GB); Fiona Frances Sarah Fletcher-Brown (Haverhill, GB)
Assignee: CAMBRIDGE ENTERPRISE LIMITED
C12Q1/6865
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,563,254
App. No.
12/524,261
Granted
Feb 18, 2020
Kind
B2
Abstract

Methods for amplifying a target nucleic acid by self-sustained amplification methods are described. The methods are designed, in particular, to be carried out without use of specialised lab facilities or instruments. Compositions, lyophilised formulations, and kits for carrying out the methods are also described.

Claims (14)

1. A universal lyophilised formulation comprising a polysaccharide, a low molecular weight saccharide, and enzyme activities required for carrying out a self-sustained amplification reaction, wherein the enzyme activities are provided by one or more enzymes, and wherein the formulation does not include cofactors or substrates required for amplification of a target nucleic acid using the enzyme activities.

2. A formulation according to claim 1 , which does not include salt.

3. A formulation according to claim 1 or 2 , wherein the polysaccharide is a dextran or a dextran derivative.

4. A formulation according to any of claims 1 to 3 , wherein the low molecular weight saccharide is trehalose, sucrose, or maltose.

5. A lyophilised formulation comprising a polysaccharide, a low molecular weight saccharide, and enzyme activities required for carrying out a self-sustained amplification reaction, wherein the enzyme activities are provided by one or more enzymes, and wherein the formulation does not include a buffering agent.

6. A formulation according to claim 5 , wherein the polysaccharide is a dextran or a dextran derivative.

7. A formulation according to claim 5 or 6 , wherein the low molecular weight saccharide is trehalose, sucrose, or maltose.

8. A formulation according to claim 5 , wherein the enzyme activities comprise an RNA-dependent DNA polymerase, a DNA-dependent DNA polymerase, a DNA/RNA duplex-specific ribonuclease, and a DNA-dependent RNA polymerase.

9. A formulation according to claim 5 , which does not include substrates or cofactors for the enzyme activities.

10. A formulation according to claim 9 , which does not include salt.

11. A kit comprising a plurality of different, separate lyophilised formulations wherein each lyophilised formulation is a lyophilised formulation according to claim 1 or 5 .

12. A universal lyophilised formulation comprising a polysaccharide, a low molecular weight saccharide, and enzyme activities required for carrying out a self-sustained amplification reaction, wherein the enzyme activities are provided by one or more enzymes, and wherein the formulation does not include cofactors or substrates required for amplification of a target nucleic acid using the enzyme activities, and wherein the formulation does not include a buffering agent, or the buffering agent is present at a concentration of less than 1 mM.

13. A universal lyophilized formulation according to claim 1 , wherein the enzyme activities comprise an RNA-dependent DNA polymerase, a DNA-dependent DNA polymerase, a DNA/RNA duplex-specific ribonuclease, and a DNA-dependent RNA polymerase.

14. A universal lyophilized formulation according to claim 12 , wherein the enzyme activities comprise an RNA-dependent DNA polymerase, a DNA-dependent DNA polymerase, a DNA/RNA duplex-specific ribonuclease, and a DNA-dependent RNA polymerase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2011
From: LEE, HELEN HWAI-AN; DINEVA, MAGDA ANASTASSOVA; FLETCHER-BROWN, FIONA FRANCES SARAH
To: CAMBRIDGE ENTERPRISE LIMITED
Reel/Frame 026012/0045 →
Priority Claims (1)
GB 0701253.7 · Jan 23, 2007 · national
Continuity (1)
Related Publication 20100136542A1 · Jun 3, 2010
Cited By (1)
US 12,559,795